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Abstract
Background:  Studies exploring molecular mechanisms underlying congenital skeletal disorders 
have revealed novel regulators of skeletal homeostasis and shown protein glycosylation to play 
an important role. 
Objective: To identify the genetic cause of rhizomelic skeletal dysplasia in a consanguineous 
Pakistani family.
Methods: Clinical investigations were carried out for four affected individuals in the recruited 
family. Whole genome sequencing (WGS) was completed using DNA from two affected and two 
unaffected individuals from the family. Sequencing data were processed, filtered and analyzed. 
In silico analyses were performed to predict the effects of the candidate variant on the protein 
structure and function. Small interfering RNAs (siRNAs) were used to study the effect of 
Gnpnat1 gene knockdown in primary rat chondrocytes.
Results:  The patients presented with short stature due to extreme shortening of the proximal 
segments of the limbs. Radiographs of one individual showed hip dysplasia and severe 
platyspondyly. WGS data analyses identified a homozygous missense variant c.226G>A; 
p.(Glu76Lys) in GNPNAT1, segregating with the disease. Glucosamine 6-phosphate N-
acetyltransferase, encoded by the highly conserved gene GNPNAT1, is one of the enzymes 
required for synthesis of uridine diphosphate N-acetylglucosamine, which participates in protein 
glycosylation. Knockdown of Gnpnat1 by siRNAs decreased cellular proliferation and 
expression of chondrocyte differentiation markers collagen type 2 and alkaline phosphatase, 
indicating that Gnpnat1 is important for growth plate chondrocyte proliferation and 
differentiation.
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Conclusions: This study describes a novel severe skeletal dysplasia associated with a biallelic, 
variant in GNPNAT1. Our data suggest that GNPNAT1 is important for growth plate 
chondrogenesis. 
 Keywords: rhizomelic dysplasia, glycosylation, chondrocyte, whole genome sequencing, 
Pakistan
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Introduction
Skeletal dysplasias are a genetically and clinically heterogeneous group of more than 400 
inherited disorders affecting bone and cartilage development or morphology [1]. Although over 
350 genes have been characterized in skeletal dysplasias, the genetic defects underlying many of 
these conditions are still unknown. Skeletal dysplasias can be classified based on clinical 
features, radiological findings and molecular mechanisms. Several skeletal dysplasias are 
associated with short stature; such disorders can be further classified based on the most severely 
affected body parts. Rhizomelic dysplasias are characterized by severe shortening and 
deformities of the proximal parts of upper (humerus) and lower (femur) limbs.
Studies into molecular mechanisms underlying skeletal dysplasias have elucidated processes that 
are important for bone homeostasis. Glycosylation, an enzymatic process involving the 
attachment of glycans to proteins and lipids [2], is a vital process in all cells and is essential for 
numerous functions, including cellular localization, transport, signaling, and metabolism of 
proteins and lipids.  Nucleotide-activated sugars serve as donors of glycan moieties during 
glycosylation. Several congenital disorders are caused by pathogenic variants affecting genes 
that encode proteins involved in glycosylation [3]. So far more than 100 congenital disorders of 
glycosylation have been described [4] and some of these conditions also feature skeletal 
anomalies [5].
We describe a consanguineous family with four adults affected by a novel form of severe 
rhizomelic skeletal dysplasia. Through whole genome sequencing, we identified a biallelic 
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missense variant in GNPNAT1 as the likely cause of their disorder. We provide evidence that 
GNPNAT1 is involved in proliferation and differentiation of chondrocytes.
Subjects and Methods
Ethics Statement
This study was approved by Institutional Review Board of School of Biological Sciences, 
University of the Punjab, Lahore, Pakistan (Ethics approval SBS11-1 by IRB # 00005281). 
Written informed consents were obtained from all participants. The animal protocol and all 
procedures were approved by the regional animal ethics committee in Stockholm, Sweden.
Subjects
A consanguineous Pakistani family NAD-07 with four affected individuals was recruited in the 
study. We collected a detailed family history about onset and progression of the disorder. 
Heights of all participating individuals were measured. Photographs of arms, legs and 
radiographs of forearms, forelegs and spine of individual IV:4 were obtained for phenotypic 
evaluation. Blood samples were obtained from all participating individuals. DNA was isolated by 
sucrose lysis and salting out method.
Molecular Analysis
Whole genome sequencing (WGS) was performed for two affected and two unaffected 
individuals. Libraries were prepared by using Illumina TruSeq PCR-free kit. Pair-end reads with 
average coverage of 30X were obtained on the HiSeq X instrument (Illumina, CA, USA) at the 
Science for Life Laboratory (SciLifeLab), Stockholm. The data were processed using our in-
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house pipeline. In brief, Burrow-Wheeler Aligner (BWA) [6] was used for mapping reads to the 
reference human genome (assembly b37). Genome Analysis Toolkit (GATK) [7] was used for 
duplicate marking, variant calling and joint genotyping. Variants were annotated using Variant 
Effect Predictor (VEP) [8] and then loaded into a database generated by GEMINI [9]. Rare 
variants (minor allele frequency <0.01 in publicly available population databases ExAC, 
gnomAD and SweGen) in the coding sequences and splice sites that supported autosomal 
recessive inheritance model were prioritized. The variants were further evaluated based on the 
conservation (GERP) and pathogenicity scores (CADD). The segregation of the variant with the 
skeletal phenotype was investigated in all family members by Sanger sequencing.
Computational Modeling of mutant protein
Human GNPNAT1 crystal structure was obtained from protein databank (PDB Identifier: 2O28). 
I-mutant 2.0 (http://folding.biofold.org/i-mutant/i-mutant2.0.html) was used to predict the effect 
of Glutamic acid to Lysine substitution at position 76 on protein stability.
Chondrocyte isolation and culture
Proximal tibias and distal femurs of 3-5 day old rats (Sprague Dawley, Charles River Laboratory, 
Wilmington, MA, USA) were obtained after dissection and digested with 0.3% collagenase type 
IA (Sigma-Aldrich, Darmstadt, Germany) in DMEM/F12 in aseptic conditio s as previously 
described [10].  Dissected cartilage pieces were washed twice in PBS with 1% 
penicillin/streptomycin, 50 ng/ml fungizone (all by Thermo Fisher Scientific, Waltham, MA, 
USA), followed by incubation in 0.1% EDTA (Sigma-Aldrich, Darmstadt, Germany) in PBS for 
15 minutes, and eventually 0.125% trypsin (Thermo Fisher Scientific) in PBS for 30 minutes, at 
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37°C in shaking conditions. Cartilage pieces were subsequently washed twice in PBS with 1% 
penicillin/streptomycin, 50ng/ml fungizone, and digested with 0.3% collagenase type IA (Sigma-
Aldrich) in DMEM/F12 at 37°C while shaking. Cycles of 30 minutes were repeated until 
digestion was complete. The resulting cell suspension was filtered through 70µm-cell strainer 
(BD Biosciences, San Jose, CA, USA), spun at 300g for 5 minutes and washed twice in PBS 
with 1% penicillin/streptomycin, 50ng/ml fungizone. The released chondrocytes were cultured in 
DMEM/F12 with GlutaMAX, with 10% fetal bovine serum (FBS), 50µg/ml ascorbic acid 
(Thermo Fisher Scientific), 50ng/ml fungizone and 1% penicillin/streptomycin at 37°C, 5% CO2. 
Gnpnat1 siRNA knock-down 
In order to determine the impact of Gnpnat1 knockdown on chondrocytes, two pre-designed 
small interfering RNAs (siRNA), Silencer™ Select siR1 (s176980) and siR2 (s176982), were 
obtained from Life Technologies® (Thermo Fisher Scientific) and used for knocking down 
Gnpnat1 in rat primary chondrocytes. Silencer™ Select Negative Control No. 1 siRNA 
(4390843; Thermo Fisher Scientific) and siRNA against Gapdh (4390849; Thermo Fisher 
Scientific) were used as negative and positive controls, respectively.
Transfection of rat primary chondrocytes with siRNAs
Rat chondrocytes (25000/cm2) were transfected with Gnpnat1 specific siRNAs or control 
siRNAs at 60% confluency, as previously described [11]. One hour prior to transfection, cells 
were washed with PBS, and culture medium was changed to DMEM/F12 without antibiotics. 
Chondrocytes were transfected with 40nM of scramble siRNA (4390843), the two siRNAs 
against Gnpnat1 (s176980 or s176982) or Gapdh siRNA as positive control, according to 
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manufacturer’s protocol, using Lipofectamine 3000 (Thermo Fisher Scientific). Culture medium 
was replaced with DMEM/F12 with GlutaMAX supplemented with 10% fetal bovine serum 
(FBS), 50µg/ml ascorbic acid, 1% penicillin/streptomycin, and 50ng/ml fungizone 16 hours post-
transfection. 
Apoptosis and proliferation assessment
Chondrocyte apoptosis and proliferation were examined 48h post-transfection. Apoptosis was 
measured by detecting cytoplasmic histone-associated DNA fragments in cell lysates 
photometrically, according to manufacturer’s instructions (Roche, Mannheim, Germany). 
Briefly, cell lysates were transferred to a streptavidin-coated plate and incubated with 
biotinylated anti-histones antibodies and anti-DNA antibodies conjugated with peroxidase. 
Washing steps were used to remove unbound components. The amount of peroxidase retained in 
the immunocomplex was determined photometrically at 405nm after substrate addition 
(tetramethyl-benzidine from Roche). 
Cell proliferation was measured by colorimetric detection based on incorporation of 5′-bromo-2′-
deoxyuridine (BrdU) (Roche) according to the standard protocol. In brief, 48h post-transfection, 
cells were incubated with BrdU for 3h, and the absorbance was measured at 370nm (SpectraMax 
Plus 384 Microplate Reader, Molecular Devices LLC, San Jose, CA, USA). As a control for 
background, incorporation in cells of BrdU was measured after only a few seconds following 
treatment.  
Quantitative real time PCR
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Gene expression was assessed 48h post-transfection. Cell lysates were collected in solution C 
(4M guanidine thiocyanate, 25mM sodium citrate pH7, 0.1M β-mercaptoethanol) and total RNA 
was extracted using phenol/chloroform [10]. cDNA was synthesized from total RNA (50ng) by 
Superscript Reverse Transcriptase III (Thermo Fisher Scientific). ABI Prism 7900 Fast Sequence 
Detector (Thermo Fisher Scientific) was used to quantify the expression of Gnpnat1, alkaline 
phosphatase (Alpl) and collagen type 2 (Col2a1) using SYBR green. Data were normalized to 
18S rRNA and relative gene expression was calculated using the algorithm: 2 -∆Ct *106 as 
previously described [12]. 
Statistical analysis
All siRNA experiments were performed in triplicates. Values are presented as average ± standard 
error of the mean (SEM). Unpaired T tests (GraphPad Prism 7.0 (GraphPad Software, Inc., La 
Jolla, CA, USA) were used to calculate significance of each siRNA-treated sample compared to 
the scrambled RNA control.
Results
Clinical Presentation
Family NAD-07 has four affected siblings born to consanguineous parents. The father and the 
only unaffected sister were deceased at the time of ascertainment. All affected individuals were 
above 40 years of age and the mother was 80 years old. The affected individuals had a similar 
phenotype including severe short stature (99 cm - 114 cm), disproportionately increased arm 
length in comparison to trunk length and large hands and feet relative to total heights (Table 1) 
(Figure 1A-D). There was marked rhizomelic shortening of the limbs. Hand and feet showed 
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irregularities in metacarpals and metatarsals length (Figure 1A-D). Affected individuals had 
abnormal gait and reported restricted joint movements accompanied by pain. Cognition was 
grossly normal as they all adequately responded to questions during the clinical examination and 
reportedly were gainfully employed. There were no clinical symptoms suggestive of impaired 
immunity. 
Radiographic Findings
Radiographs of an affected individual IV:4 indicated several skeletal anomalies (Figure 2A-2F). 
Spinal radiographs revealed platyspondyly involving the whole spine (Figure 2C). Radiographs 
of the upper arms showed short humeri with underdeveloped proximal parts. Pelvic radiograph 
indicated hip dysplasia with deformed proximal femurs, absent caput femur and short femoral 
neck. Femurs were short and the metaphyseal regions around the knees were very wide and 
abnormal in shape (Figure 2A- 2F). 
Molecular Investigation
Whole genome sequencing of four family members revealed 21 variants that were homozygous 
in the affected individuals and heterozygous in the mother with a MAF < 0.01 (Table S1). Of 
these, only one homozygous exonic variant in GNPNAT1 c.226G>A; p.(Glu76Lys)  was 
identified after applying filtration criteria. The variant segregated with the disease phenotype in 
the family. All affected individuals were homozygous for the variant while the mother was 
heterozygous and the unaffected niece (V:I) was homozygous for the wild-type allele (Figure 
3A, 3B). The variant was absent in all public databases including gnomAD and 1000 genomes as 
well as in 380 ethnically matched control chromosomes. The variant was predicted to be 
pathogenic by Polyphen2 and MutationTaster with a Combined Annotation Dependent Depletion 
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(CADD) score of 22. The GNPNAT1 c.226G>A; p.(Glu76Lys) variant was deposited in LOVD 
(LOVD# 0000645198). 
Results of computational modeling
Computational modeling of the crystal structure of GNPNAT1 predicted a large decrease in 
stability (DDG Value Prediction, -0.70 Kcal/mol) of the enzyme due to the amino acid 
substitution at position 76 (p.Glu76Lys). 
Chondrocyte apoptosis is unaffected by Gnpnat1 knockdown 
Gnpnat1 expression was decreased by 4.9-fold (p<0.001) and 3.3-fold (p<0.001) by siR1 and 
siR2 respectively, 48 hours after transfection, as compared to chondrocytes transfected with 
scrambled siRNA (Figure 4A). Cell proliferation was significantly reduced in the chondrocytes 
transfected with siR2 (p<0.05), but the reduction did not reach significance in chondrocytes 
transfected with siR1 (Figure 4B). Chondrocyte apoptosis was not affected by any of the 
Gnpnat1 siRNAs 48 hours after transfection (Figure 4C).
Knockdown of Gnpnat1 induces de-differentiation of chondrocytes 
To investigate whether Gnpnat1 knockdown influences chondrocyte differentiation, we studied 
the expression levels of chondrocyte marker Col2a1 and hypertrophic chondrocyte marker Alpl. 
Both Alpl expression and Col2a1 expressions were significantly reduced in chondrocytes 
transfected by siR1, by 1.6-fold (p<0.01) and 2.1-fold (p<0.001), respectively (Figure 4D, 4E). 
Gnpnat1 knockdown induced chondrocyte de-differentiation, as the expression of chondrocyte 
differentiation markers was reduced.
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Discussion
We describe a novel autosomal recessive skeletal dysplasia in a consanguineous family. A 
homozygous missense variant c.226G>A; p.(Glu76Lys)  in GNPNAT1 was identified by whole 
genome sequencing as the likely cause of the disorder in the studied family. The affected 
individuals had rhizomelic shortening of limbs and severe short stature. 
Inside the Golgi complex, the dolichol-pyrophosphate oligosaccharide, which is transferred to 
nascent proteins, receives its first monosaccharide from uridine diphosphate N-
acetylglucosamine (UDP-GalNAc) during N-glycosylation of secretory/membrane protein.  
Moreover, synthesis of glycosaminoglycans, proteoglycans and glycosylphosphatidylinositol 
(GPI) anchors also require UDP-GalNAc as the glycan donor. Endogenous UDP-GalNAc is 
synthesized from N-acetyl-alpha-D-glucosamine 1-phosphate de novo or from salvage pathways.  
The synthesis of UDP-GalNAc is a four-step process and the second step is catalyzed by 
glucosamine 6-phosphate N-acetyltransferase (GNPNAT1), encoded by GNPNAT1. GNPNAT1 
is a small dimeric protein localized in the Golgi and endosome membranes. 
The dimeric structure of GNPNAT1 is stabilized by salt bridges and interactions between amino 
acids situated at the interfacing regions of monomers [13]. The charge density at the interface 
and the binding site further stabilizes the protein structure and its catalytic activity. The glutamic 
acid residue at position 76, substituted by lysine (p.(Glu76Lys)), is evolutionarily conserved 
among diverse vertebrate species (Figure 5A). The variant affects the acetyltransferase domain 
of the enzyme (Figure 5B). Moreover, the change from an acidic amino acid to a basic amino 
acid affects the charge distribution of the enzyme as well. Therefore, it is likely that the 
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p.(Glu76Lys) variant will significantly affect the activity and function of this enzyme. The 
computational modeling also predicted a decreased stability of the enzyme due to the variant. 
Among the orthologues, knocking out Gnpnat1 in Saccharomyces cerevisiae is lethal [14] and 
homozygous null mutants of murine Gnpnat1 exhibit a generalized reduction of cell proliferation 
and development of embryos, resulting in death at 7.5 embryonic day [15]. The mutant mouse 
embryonic fibroblasts also exhibit impaired actin bundles depolymerization and resistance to 
apoptotic signals. These cellular defects are rescued by feeding cells with exogeneous UDP-
GalNAc. [15]. Thus, taken together these results suggest that intracellular UDP-GalNAc 
deficiency affects apoptotic and proliferation signaling.  
Interestingly, genetic variants in PGM3 (OMIM 172100) encoding the phosphoglucomutase-3, 
which is involved in the third step of the synthesis of N-acetyl-alpha-D-glucosamine 1-phosphate 
(UDP-GalNAc), have been identified in a form of autosomal recessive skeletal dysplasia 
resembling Desbuquois dysplasia (OMIM 251450) [16]. The phenotype of the affected 
individuals harboring the GNPNAT1 variant in our family resembles that of the patients with 
PGM3 variants, who also feature a rhizomelic shortening of the long bones. However, in our 
patients with the GNPNAT1 defect, rhizomelia was more severe, especially in the upper limbs. 
At least the proband, homozygous for the GNPNAT1 variant for whom spinal radiographs were 
available, had severe platyspondyly as reported for the infants with the PGM3 variants [16]. The 
shortened femoral necks and severe dysplasia of the proximal femur due to the GNPNAT1 
variant resembles that seen in patients with the PGM3 variants. However, the proximal femur 
develops significantly during the first years of life and since all patients with the PGM3 
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mutations were infants at the time of phenotypic description, the effects of these mutations on the 
adult skeleton are unknown. The affected individuals in our family did not have mid-face 
hypoplasia as observed for patients harboring PGM3 variants. The patients with PGM3 variants 
were also anemic and had an immune deficiency. Blood chemistry profiles of the affected 
individuals in our study were not available for comparison but the patients lacked clinical history 
suggestive of an increased number or severity of infections. Unfortunately, the family in this 
study lives in a remote area with restricted access to health care and only limited medical data 
could be obtained. Our search for additional patients with GNPNAT1 mutations in our own, or 
international collaborators’ databases of exome data from skeletal dysplasia patients, or through 
Genematcher were not successful.
Two other conditions bear some resemblance to the skeletal dysplasia described here. 
Autosomal-recessive omodysplasia (OMIM 258315) is characterized by proximally shortened 
limbs, facial dysmorphism, and severe short stature. Skeletal features include proximal limb 
shortening with distal tapering of long bones, proximal radioulnar diastasis, and anterolateral 
dislocation of the radial head. Facial features include frontal bossing, a flat nasal bridge and 
anteverted nostrils, low set ears, a long philtrum, and frontal capillary hemangiomas. Adult 
height ranges from -7.0 to -5.5 SD. The disease is caused by point mutations or by larger 
genomic rearrangements in glypican 6 (GPC6) [17]. Although some of the skeletal changes 
overlap, our patients did not have the facial characteristics of patients with omodysplasia. 
Second, the heterogeneous group of cases reported as Patterson-Lowry syndrome have features 
overlapping those of our patients, especially the proximal humeral deformity [18]. The original 
case, an elderly adult, also showed some platyspondyly but the spinal changes were not as severe 
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as seen in our patient [19]. Metacarpal shortening, as observed in our patients, has also been 
described [20]. Recessive inheritance has been suggested [18] but the genetic cause remains 
unknown; severity varies from early lethality [21] to relatively mild short stature [20].  
Knockdown of Gnpnat1 in rat primary chondrocytes provided support for the importance of 
Gnpnat1 in chondrogenesis. Knockdown of Gnpnat1 using siRNA significantly decreased 
proliferation and expression of chondrogenic marker genes Col2a1 and Alpl. These results 
suggested that Gnpnat1 is necessary for proliferation and differentiation of chondrocytes; two 
crucial processes during skeletal formation and growth. Interestingly, siRNA knockdown of 
Gnpnat1 did not induce apoptosis in primary rat chondrocytes, thus suggesting that Gnpnat1 is 
not necessary to prevent apoptosis. Our findings of decreased chondrocyte proliferation with 
Gnpnat1 knockdown, taken together with the previous findings of reduced fibroblasts 
proliferation in Gnpnat1 deficient mice [15] may suggest that Gnpnat1 has an important function 
during cell proliferation in several cell types, not just chondrocytes. The mechanism for this role 
is not currently understood and needs to be addressed in future studies. 
In summary, these findings broadly support the hypothesis that GNPNAT1 has an important role 
during formation and growth of the endochondral skeleton. The fact that our patients with a 
GNPNAT1 missense variant had a severe skeletal disorder and survived until adulthood while 
knocking out orthologues of GNPNAT1cause lethality in mice and yeast, may imply that the 
variant identified in our family could lead to production of GNPNAT1 which is partially 
functional. Further studies including generation of conditional knockout and hypomorphic 
animal models are necessary to elucidate the exact role of GNPNAT1 in cartilage and bone 
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development, cell proliferation and skeletogenesis. Additional patient reports are needed to 
delineate in more detail the clinical course and characteristics of this novel form of skeletal 
dysplasia.
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Legends
Figure 1: Photographs of the affected individuals IV:4 and IV:5.
 A. Photograph of IV:4 showing disproportionate short stature with rhizomelia and relative 
macrocephaly, normal facial features, long arms and large hands relative to body length, and 
very short forearms (arrow). B. Photographs of IV:5 showing short forearms (arrow) and 
irregular length of metacarpal bones and shortness of the 4th metacarpal (arrow). C. IV:5 also has 
mild lower leg varus deformity and long arms and large feet relative to total height. D. 
Photograph of the feet of IV:4 showing irregular metatarsal bone length bilaterally (arrows) 
leading to overlapping toes.
Figure 2: Radiographs of individual IV:4 at 50 years. 
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A. Radiograph of the chest shows severe platyspondyly. B.  All lumbar vertebrae are similarly 
flat and show significant degenerative changes C. A lateral image of the thoracic and lumbar 
spine shows that platyspondyly involves all vertebrae. D. Radiographs of the arms show 
shortening of the humeri bilaterally with underdeveloped proximal humerus (arrows). The radius 
and ulna appear normal in length and shape. E. Similarly, the femur is short, and the proximal 
femoral head is underdeveloped. Distal femur is abnormally wide F. A closer view of the left hip 
showing abnormal shapes of the proximal femur and the acetabulum. 
Figure 3: Family NAD-07 and segregation of GNPNAT1 variant. 
A. Pedigree of family NAD-07. Consanguinity is indicated by double lines, filled symbols 
denote homozygous affected individuals and symbols with dots denote the heterozygous carriers 
of the variant. Asterisk (*) denotes the individuals who have been screened by WGS. Genotypes 
for GNPNAT1 variant c.226G>A are given for all participants below their symbols. B. Partial 
chromatograms showing the mutation site of GNPNAT1. Arrows indicate the point of mutation.
Figure 4: Knockdown of Gnpnat1 reduces proliferation of rat primary chondrocytes and induces 
dedifferentiation.
A. Expression of Gnpnat1 was significantly reduced upon transfection with two siRNAs (siR1 
and siR2) against Gnpnat1.B. Proliferation of rat primary chondrocytes upon transfection with 
siRNAs was significantly reduced as measured by BrdU incorporation. C. K ockdown of 
Gnpnat1 by transfection with either of two siRNAs did not affect apoptosis in rat primary 
chondrocytes. D. Alpl expression as well as (E) Col2a1 expression was significantly reduced 
upon transfection with either of the siRNAs. All measurements are performed 48h post end 
transfection. Bars indicate Average ± SEM of two independent experiments (*, p<0.05; **, 
p<0.01; ***, p<0.001 relative to scrambled-treated cells).
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Figure 5: Amino acid conservation and schematic representation of GNPNAT1.
A. Clustal Omega multiple sequence alignment of GNPNAT1 from diverse vertebrate species 
showing conservation of Glutamic acid at position 76 in all orthologues. The conserved amino 
acids are highlighted in yellow. The asterisk signs below the alignment represent evolutionary 
conserved amino acids, the colon indicates an highly conserved amino acid, and the periods 
symbolize less conserved amino acid. B. Graphical representation of GNPNAT1, in which the 
grey area indicates the acetyltransferase domain. Amino acids are numbered with integers and 
the genetic variant is marked.
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Table 1: Phenotypic features of NAD-07 family members.
cm: centimeters, SD: standard deviation score. NA, not available











III:1 80 F Heterozygous 155 -1.3 NA NA Normal Normal Normal
IV:1 48 M Homozygous 109 -9.4 58 +2.0 Normal Abnormal Normal
IV:4 50 M Homozygous 104 -10.1 58 +2.0 Normal Abnormal Normal
IV:5 45 F Homozygous 99 -9.9 56 +1.5 Normal Abnormal Normal
IV:6 46 F Homozygous 114 -7.6 53 -1.3 Normal Abnormal Normal
V:1 22 F Wild type 154 -1.4 - - Normal Normal Normal
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Figure 1: Photographs of the affected individuals IV:4 and IV:5. 
A. Photograph of IV:4 showing disproportionate short stature with rhizomelia and relative macrocephaly, 
normal facial features, long arms and large hands relative to body length, and very short forearms (arrow). 
B. Photographs of IV:5 showing short forearms (arrow) and irregular length of metacarpal bones and 
shortness of the 4th metacarpal (arrow). C. IV:5 also has mild lower leg varus deformity and long arms and 
large feet relative to total height. D. Photograph of the feet of IV:4 showing irregular metatarsal bone length 
bilaterally (arrows) leading to overlapping toes. 
237x133mm (300 x 300 DPI) 
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Figure 2: Radiographs of individual IV:4 at 50 years. 
A. Radiograph of the chest shows severe platyspondyly. B.  All lumbar vertebrae are similarly flat and show 
significant degenerative changes C. A lateral image of the thoracic and lumbar spine shows that 
platyspondyly involves all vertebrae. D. Radiographs of the arms show shortening of the humeri bilaterally 
with underdeveloped proximal humerus (arrows). The radius and ulna appear normal in length and shape. E. 
Similarly, the femur is short, and the proximal femoral head is underdeveloped. Distal femur is abnormally 
wide F. A closer view of the left hip showing abnormal shapes of the proximal femur and the acetabulum. 
211x96mm (300 x 300 DPI) 
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Figure 3: Family NAD-07 and segregation of GNPNAT1 variant. 
A. Pedigree of family NAD-07. Consanguinity is indicated by double lines, filled symbols denote homozygous 
affected individuals and symbols with dots denote the heterozygous carriers of the variant. Asterisk (*) 
denotes the individuals who have been screened by WGS. Genotypes for GNPNAT1 variant c.226G>A are 
given for all participants below their symbols. B. Partial chromatograms showing the mutation site of 
GNPNAT1. Arrows indicate the point of mutation. 
85x114mm (300 x 300 DPI) 
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Figure 4: Knockdown of Gnpnat1 reduces proliferation of rat primary chondrocytes and induces 
dedifferentiation. 
A. Expression of Gnpnat1 was significantly reduced upon transfection with two siRNAs (siR1 and siR2) 
against Gnpnat1.B. Proliferation of rat primary chondrocytes upon transfection with siRNAs was significantly 
reduced as measured by BrdU incorporation. C. Knockdown of Gnpnat1 by transfection with either of two 
siRNAs did not affect apoptosis in rat primary chondrocytes. D. Alpl expression as well as (E) Col2a1 
expression was significantly reduced upon transfection with either of the siRNAs. All measurements are 
performed 48h post end transfection. Bars indicate Average ± SEM of two independent experiments (*, 
p<0.05; **, p<0.01; ***, p<0.001 relative to scrambled-treated cells). 
127x69mm (300 x 300 DPI) 
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Figure 5: Amino acid conservation and schematic representation of GNPNAT1. 
A. Clustal Omega multiple sequence alignment of GNPNAT1 from diverse vertebrate species showing 
conservation of Glutamic acid at position 76 in all orthologues. The conserved amino acids are highlighted in 
yellow. The asterisk signs below the alignment represent evolutionary conserved amino acids, the colon 
indicates an highly conserved amino acid, and the periods symbolize less conserved amino acid. B. Graphical 
representation of GNPNAT1, in which the grey area indicates the acetyltransferase domain. Amino acids are 
numbered with integers and the genetic variant is marked. 
165x119mm (300 x 300 DPI) 
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Table S1: Homozygous variants with MAF < 0.01 identified after the analysis of WGS data.
Chr Positiona Reference sequence
Altered 
Sequence Gene Transcript Exonic ExAC Conserved
CADD 
score
1 11838347 CAAA C RP11-56N19.5
ENST0000











































0523197 No 0 No None
8
11801921
8 TTTTTC T SLC30A8
ENST0000
0521035 No 0 No None




0421645 No 0 No 3.53
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a positions are according to human UCSC Genome Browser Feb. 2009 (GRCh37/hg19)
9 37767509 C A EXOSC3
ENST0000
0465229 No 0 No 0.02
14 39308411 G GA LINC00639
ENST0000
0553932 No 0 No None
14 45366778 G A C14orf28
ENST0000
0325192 No 0 Yes 13.83
14 53248620 C T GNPNAT1
ENST0000
0216410 Yes 0 Yes 22.9




0558742 No 0 No None
15 75933564 CA C IMP3
ENST0000





0560044 No 0 No None
17 61198173 CAA C RP11-556O9.2
ENST0000
0582889 No 0 No None
18 2977188 CA C LPIN2
ENST0000





0578278 No 0 No None
19 1583385 CA C MBD3
ENST0000
0585903 No 0 No None
19 15087848 GAAAAA G SLC1A6
ENST0000
0601761 No 0 No None
19 2015539 GGGC G BTBD2
ENST0000
0255608 Yes 0 No None
X 27765398 AGAG A DCAF8L2
ENST0000
0451261 Yes 0 No None
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